Icatibant Glenmark

Icatibant, the active ingredient in Icatibant Glenmark, is a bradykinin B2 receptor antagonist presented as a 30 mg per 0.3 mL prefilled syringe solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other regulated markets.

Icatibant is used to manage hereditary angioedema by blocking the bradykinin pathway.

Hereditary angioedema (C1‑inhibitor deficiency): provides rapid reduction of swelling during acute attacks. Hereditary angioedema (type I/II): alleviates edema and associated pain when an attack occurs. Hereditary angioedema (type III/normal C1‑inhibitor): can be employed for acute symptom control in regions where approved.

The most frequently reported reactions to icatibant are related to the injection site, while rare events may involve systemic hypersensitivity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: redness around the injection area. - Swelling: localized edema at the site. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or airway: potentially life‑threatening swelling. - Hypotension: sudden drop in blood pressure, may cause dizziness.

When prescribing icatibant, clinicians should consider several safety and handling factors.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. Renal impairment: no dose adjustment required, but monitor for accumulation. Concomitant ACE inhibitors or ARBs: may increase risk of angioedema; observe closely. Hypersensitivity: discontinue treatment if signs of allergic reaction appear. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other agents that influence the bradykinin system or fluid balance.

Major Interactions (Avoid): - ACE inhibitors: combined use can heighten the risk of angioedema. - Concurrent use of ARBs with ACE inhibitors: avoid due to additive bradykinin effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may exacerbate hereditary angioedema; monitor symptoms. - Diuretics: can affect plasma volume; observe for changes in edema. - Other bradykinin‑targeting therapies (e.g., ecallantide): monitor for additive effects on blood pressure and swelling.